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Depression is one of the most common mental disorders among
adults.1,2 Major depression in particular ranks currently fourth
in disease burden worldwide, and is expected to rank first in
high-income countries by 2030.3 In addition, depression is an
enormous societal burden due to high healthcare use and reduced
work performance.4–6 Furthermore, depression is associated with
substantial impairments in quality of life.7,8 Quality of life
(QoL) is a broad concept that comprises a range of life domains
of the individual, such as social relationships, physical abilities,
mental health functioning, role functioning and engagement in
daily activities. Deficits in all these domains have been identified
in people experiencing depressive symptoms.9 Several meta-analyses
have shown the effectiveness of different psychotherapies in reducing
depressive symptoms compared with control conditions.10,11 Even
though it is often postulated that improvements in depressive
symptoms during treatment coincide with improvements in
QoL, evidence to support the effectiveness of depression treatment
on QoL is limited.12 Research indicates that QoL and depressive
symptoms are moderately correlated at post-treatment assessment
but suggest a weaker relationship in the long term.13 Additionally,
research suggests that people in remission from depression
experience persistent deficits in QoL.14,15 Therefore, clinical
remission, as well as overall well-being, defined exclusively by
the absence of depressive symptoms, may be insufficient. To date,
no meta-analysis has quantified the effects of psychotherapy for
depression on QoL. Therefore, we examined how the effects of
psychotherapy for depression compared with control conditions
on global QoL and on two specific domains of QoL, namely
mental and physical health.
Method
Initially, we searched an existing database (www.evidencebased
psychotherapies.org) that has previously been used in a series of
meta-analyses and contains 1476 randomised controlled trials
(RCTs).16 This database was developed through a systematic
literature search (from 1966 to 1 January 2013) and is periodically
updated. Additionally, a systematic literature search was
conducted in PubMed, EMBASE, PsycINFO and the Cochrane
Central Register of Controlled Trials from 1 January 2013 to 1
January 2015.
Study selection
We included published RCTs in which psychotherapy for
depression was compared with a control condition, for
participants 18 years old or over, and which reported a measure
of QoL at post-treatment assessment. Psychotherapy was defined
as an intervention in which the core element was verbal
communication between a participant and a therapist, or as a
systematic psychological treatment in the form of a website or
book which the participant worked through more or less
independently but with personal support from a therapist.16 The
control condition was defined as waiting list, care as usual, placebo
or another minimal treatment. Studies were included if
participants were diagnosed with a depressive disorder on the
basis of a structured clinical interview or if they reported elevated
depressive symptoms based on a standardised measurement of
depressive symptom severity. A measure of QoL was defined as
any patient-reported measure aiming to assess perceived health
status, well-being or effective performance in daily life.17 These
measures could provide a global (overall) score, or separate scores
for different domains or components. We differentiated between
two components, namely mental health and physical health. The
mental health component of QoL was defined as personal
satisfaction with the current psychological state, whereas the
physical health component was defined as the perceived
competence for performance and functioning in various everyday
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Background
Several meta-analyses have shown that psychotherapy is
effective for reducing depressive symptom severity.
However, the impact on quality of life (QoL) is as yet
unknown.
Aims
To investigate the effectiveness of psychotherapy for
depression on global QoL and on the mental health and
physical health components of QoL.
Method
We conducted a meta-analysis of 44 randomised clinical
trials comparing psychotherapy for adults experiencing
clinical depression or elevated depressive symptoms with a
control group. We used subgroup analyses to explore the
influence of various study characteristics on the effectiveness
of treatment.
Results
We detected a small to moderate effect size (Hedges’
g= 0.33, 95% CI 0.24–0.42) for global QoL, a moderate effect
size for the mental health component (g= 0.42, 95% CI 0.33–
0.51) and, after removing an outlier, a small but statistically
significant effect size for the physical health component
(g= 0.16, 95% CI 0.05–0.27). Multivariate meta-regression
analyses showed that the effect size of depressive symptoms
was significantly related to the effect size of the mental
health component of QoL. The effect size of depressive
symptoms was not related to global QoL or the physical
health component.
Conclusions
Psychotherapy for depression has a positive impact on the
QoL of patients with depression. Improvements in QoL are
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activities.17 Our search was restricted to studies written in English
and German. Studies regarding treatment maintenance were
excluded. Comorbid psychiatric or medical disorders were not
used as an exclusion criterion. Finally, we excluded studies
for which we did not have sufficient statistics to perform the
meta-analysis.
Quality assessment
The validity of the studies was assessed following the guidelines
provided by the Cochrane Collaboration’s tool for assessing risk
of bias.18 Risk of bias was examined in four domains: random
sequence generation, allocation concealment, blinding (masking)
of outcome assessment and intention-to-treat analysis. Two
authors (S.K. and A.K.) conducted the assessment. Disagreements
between the two reviewers were resolved by discussion until
consensus was reached.
Statistical analysis
For the univariate analyses we used the Comprehensive Meta-
Analysis (CMA) software package.19 For the multivariate analyses
we used the metareg module within Stata,20 because these analyses
cannot be performed with CMA. We calculated the effect size
following the procedure described by Hedges & Olkin to correct
for small sample size bias.21 We estimated the pooled effect sizes
using the random effects model to account for heterogeneity
among studies.22 Heterogeneity was examined with the I 2 statistic,
where a value of 25% determines low heterogeneity, 50%
moderate heterogeneity and 75% high heterogeneity.23 We further
calculated the 95% confidence intervals around I 2 statistic,24 by
using the non-central w2-based approach within the heterogi
module for Stata.25 Finally, publication bias was examined by
visual inspection of the funnel plot and by implementing Duval
& Tweedie’s trim and fill procedure, which is a test of symmetry
of the funnel plot. In addition, the method developed by Duval
& Tweedie yields an adjusted pooled effect size after accounting
for missing studies due to publication bias.26 We conducted a
number of subgroup analyses to identify potential moderators
of the outcome using the mixed effects model, in which studies
within the subgroups are pooled with the random effects model
and the tests for significant differences between the subgroups
are carried out with the fixed effects model.27 Subgroup analyses
were performed when at least three studies were available for each
group. Moreover, we conducted sensitivity analyses because a
number of studies compared more than one experimental group
with the same control condition, and therefore the assumption
of independency was violated. In the sensitivity analyses we first
included the largest effect size for each study and then the lowest
effect size for each study.
We used univariate and multivariate meta-regression analyses to
examine the relationship between changes in QoL and depressive
symptom severity. The meta-regressions were undertaken using
the mixed effects model.28 For the univariate meta-regressions
the effect size of QoL was set as the dependent variable and
the effect size of depressive symptom severity as the predictor.
For the multivariate meta-regressions a number of potential
confounder variables were added simultaneously as predictors
alongside the effect size for depressive symptoms.
Power calculation
We presumed that a limited number of studies would have
administered QoL measures. Thus, we carried out a power
calculation to estimate whether the included studies would
provide sufficient statistical power to detect small effect sizes,
according to the recommendations of Borenstein et al.27 Although
there is no consensus about a clear definition, we defined a small
effect size as g= 0.20.29 We conservatively assumed a high level of
between-study variance (t2), a statistical power of 0.80 and an
alpha value of 0.05. The power calculation demonstrated that
we would need 20 studies with a mean sample size of 40
participants or 15 studies with 54 participants.
Results
The databases search resulted in 20 461 titles. We retrieved the full
text of 1764 studies, from which 44 studies were included in this
meta-analysis (Fig. 1).
Study characteristics
The 44 studies included in total 5264 patients: 2907 in the inter-
vention group and 2357 in the control group (see online Table
DS1). More specifically, the meta-analysis of global QoL included
27 studies with 2448 patients, the meta-analysis of the mental
health component included 18 studies with 2463 patients and
that of the physical health component included 13 studies with
1561 patients. Psychotherapies that could be clustered in the
cognitive–behavioural group (i.e. cognitive–behavioural therapy,
mindfulness-based cognitive therapy and coping with depression)
were provided in 25 studies (56%). Life review was offered in five
studies (14%), problem-solving treatment in three studies (8%),
acceptance and commitment therapy in three studies (8%) and
interpersonal psychotherapy in two studies (5%). Care as usual
was the most common control condition and was included in
20 studies (45%). It consisted mainly of psychotherapy, anti-
depressant medication or combination treatments, but was only
superficially described in the published papers. Therefore, we
did not have enough information to cluster usual treatments
based on their modality. Waiting-list groups were included in 17
studies (39%). Other types of control conditions were included
in 7 studies (16%), and consisted of discussion groups, psycho-
education, a 20 min educational video or placebo pill. The mean
number of treatment sessions was 10 (median 9, range 1–25).
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20 461
(PubMed 5191, PsycINFO 3532,
EMBASE 6768, Cochrane 4970)
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Fig. 1 Study selection.
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All the quality criteria were met by 24 studies (55%) and at least
three out of four criteria were met by 33 studies (75%). Finally, 36
studies (82%) reported a method of handling incomplete outcome
data. The characteristics of the participants varied among the
studies. Adult patients (both men and women) were included in
27 studies (61%), older adults in 11 studies (25%) and exclusively
women in six studies (14%). Eighteen studies (41%) included
participants diagnosed with major depressive disorder. Patients
with comorbid physical or mental health symptoms were included
in 15 studies (34%).
Global QoL
Thirty-one comparisons were included in the meta-analysis of
global QoL (Fig. 2). The mean effect size (Hedges’ g) was 0.33
(95% CI 0.24–0.42). We detected low between-study heterogeneity
(I 2 = 21, 95% CI 0–49). After adjusting for publication bias using
the trim and fill procedure the mean effect size was g= 0.30 (95%
CI 0.21–0.40), with three imputed studies (Table 1). Moreover,
meta-analysis including only the largest effect size of each study
resulted in an overall effect size of g = 0.35 (95% CI 0.25–0.45).
When only the smallest effect size was included the pooled effect
size was g= 0.34 (95% CI 0.24–0.45). We also calculated the effect
sizes separately for scores on the Quality of Life Inventory (QOLI;
g= 0.32, 95% CI 0.15–0.48) and the EuroQol EQ-5D (g= 0.19,
95% CI 0.07–0.32). Studies including people with major
depressive disorder resulted in larger effect sizes (g= 0.49, 95%
CI 0.36–0.61) than studies including people without such a
diagnosis (g= 0.23, 95% CI 0.13–0.34, P= 0.002). Studies
including adults reported larger effect sizes (g= 0.39, 95% CI
0.29–0.49) than studies including older adults (g= 0.15, 95% CI
0.00–0.30, P= 0.009). Other study characteristics were not
significantly related to the effect size of global QoL.
The mean effect size for depressive symptoms was g= 0.60
(95% CI 0.50–0.70) and therefore considerably larger than that
for global QoL. Heterogeneity was moderate (I 2 = 32%, 95% CI
0–56). After adjusting for publication bias the mean effect size
decreased to g= 0.54 (95% CI 0.44–0.64), with five imputed studies.
The univariate meta-regression analysis indicated a significant
relationship between the effect size of global QoL and the effect
size of depressive symptoms (slope 0.52, 95% CI 0.21–0.84,
P= 0.002), suggesting that with each increase in effect size of
depressive symptom severity by 1 the effect size for global QoL
increased by 0.52. The effect size of global QoL was not
significantly associated with the number of treatment sessions (slope
0.00, 95%CI 70.03 to 0.03, P= 0.803). The multivariate meta-
regression results showed that none of the predictors included in
the model was significantly related to the effect of psychotherapy
on global QoL at post-treatment assessment (see Table 4).
Mental health
Twenty-one comparisons were included in the meta-analysis of
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Fig. 2 Standardised effect sizes (Hedges’ g) of psychotherapy for depression compared with control conditions on global quality of life.
CBT, cognitive–behavioural therapy (em, email therapy; sh, guided self-help; st, standard treatment; tai, tailored treatment); PST, problem-
solving therapy; SUP, supportive therapy.
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component of QoL compared with a control condition. The mean
effect size was g= 0.42 (95% CI 0.33–0.51). We detected low
between-study heterogeneity (I 2 = 3, 95% CI 0–54). After
adjustment for publication bias the mean effect size was g= 0.37
(95% CI 0.28–0.47), with five imputed studies (Table 2).
Additionally, we performed a meta-analysis including the largest
effect size of each study, which resulted in an overall effect size
of g = 0.43 (95% CI 0.32–0.53). When the smallest effect size
was included the pooled effect size was g= 0.40 (95% CI 0.31–
0.50). Finally we conducted a series of subgroup analyses, but
none of the included moderators was significantly related to the
effect size of the mental health component (Table 2). For this
group of studies the mean effect size for depressive symptoms
was g= 0.48 (95% CI 0.36–0.60). Between-study heterogeneity
was moderate to high (I 2 = 55, 95% CI 17–72). After adjusting
for publication bias the effect size decreased (g= 0.41, 95% CI
0.28–0.54), with four missing studies.
Meta-regression analysis indicated a significant association
between the effect size of the mental health component of QoL
and the effect size of depressive symptoms at post-treatment
measurement (slope 0.49, 95% CI 0.19–0.80, P= 0.003). The
results suggested that with each increase in effect size of depressive
symptom severity by 1 the effect size for the mental health
component of QoL increased by 0.49 (Fig. 3). The effect size of
the mental health component was not significantly related to the
number of treatment sessions (slope 0.01, 95% CI 70.01 to
0.03, P= 0.544). The multivariate meta-regression analysis
demonstrated that only the effect size of depression severity was
a significant predictor of the effect of psychotherapy on the mental
health component QoL (b= 0.50, 95% CI 0.16–0.83, P= 0.007; see
Table 4).
Physical health
Fourteen comparisons were included in the meta-analysis of the
physical health component of QoL (Table 3). The mean effect size
was g= 0.27 (95% CI 0.07– 0.46). We detected high between-study
heterogeneity (I 2 = 70, 95% CI 41–81). We repeated the analysis
after removing an outlier with an effect size of g = 2.16.30 The
pooled effect size decreased (g= 0.16, 95% CI 0.05–0.27); in
addition heterogeneity was low (I 2 = 4, 95% CI 0–49). We
adjusted for publication bias and the mean effect size decreased
to g= 0.13 (95% CI 0.01–0.25), with two studies missing The
meta-analysis including the largest effect sizes of each study
resulted in an overall effect size of g = 0.16 (95% CI 0.04–0.28).
Next we included the smallest effect sizes, resulting in an overall
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Table 1 Global quality of life: effect sizes in meta-analysis of studies comparing psychotherapy with a control group
Number of
Effect size Heterogeneityb
Comparisona comparisons g 95% CI I 2 95% CI P
All studies 31 0.33*** 0.24–0.42 21 0–49
Adjusted values 34 0.30 0.21–0.40
Effect size for depression 31 0.60*** 0.50–0.70 32 0–56
Adjusted values 36 0.54 0.44–0.64
One effect size per study (highest) 27 0.35*** 0.25–0.45 25 0–53
One effect size per study (lowest) 27 0.34*** 0.24–0.45 28 0–55
QOLI 8 0.32*** 0.15–0.48 0 0–56
EQ-5D 8 0.19** 0.07–0.32 0 0–56
Subgroup analyses
MDD
Yes 15 0.49*** 0.36–0.61 0 0–46 0.002
No 16 0.23*** 0.13–0.34 6 0–48
Comorbidity
Yes 10 0.23** 0.08–0.38 0 0–53 0.148
No 21 0.37*** 0.26–0.49 31 0–59
Control group
Care as usual 10 0.18** 0.05–0.32 1 0–53 0.053
Waiting list 14 0.42*** 0.28–0.56 23 0–59
Other 7 0.33*** 0.16–0.50 0 0–58
Intent-to-treat analysis
Yes 27 0.34*** 0.24–0.43 25 0–53 0.895
No 4 0.32* 0.03–0.60 5 0–69
Treatment type
Individual 10 0.17* 0.01–0.33 0 0–53 0.258
Group 8 0.35** 0.13–0.57 52 0–77
Internet-based treatment
Yes 12 0.41*** 0.28–0.53 3 0–51 0.331
No 19 0.27*** 0.15–0.40 26 0–57
Target group
Adults in general 23 0.39*** 0.29–0.49 11 0–47 0.009
Older adults 8 0.15 70.00–0.30 0 0–56
CBT v. other
CBT 20 0.36*** 0.25–0.47 21 0–54 0.429
Other 11 0.28*** 0.13–0.44 18 0–60
Life review v. other
Life review 5 0.19 70.05–0.42 27 0–73 0.171
Other 26 0.37*** 0.26–0.43 11 0–45
CBT, cognitive–behavioural therapy; MDD, major depressive disorder; QoL, quality of life; QOLI, Quality of Life Inventory.
a. The data presented here are from analysis using the random effects model.








Comparisona comparisons g 95% CI I 2 95% CI P
All studies 21 0.42*** 0.33–0.51 23 0–54
Adjusted values 26 0.37 0.28–0.47
Effect size for depression 20 0.48*** 0.36–0.60 55 17–72
Adjusted values 24 0.41 0.28–0.54
One effect size per study (highest) 18 0.43*** 0.32–0.53 29 0–59
One effect size per study (lowest) 18 0.40*** 0.31–0.50 17 0–53
Subgroup analyses
MDD
Yes 6 0.49*** 0.34–0.64 0 0–61 0.277
No 15 0.39*** 0.28–0.50 34 0–63
Comorbidity
Yes 7 0.34** 0.12–0.56 46 0–76 0.428
No 14 0.43*** 0.35–0.52 1 0–48
Control group
Care as usual 13 0.38*** 0.25–0.51 37 0–66 0.242
Waiting list 7 0.48*** 0.36–0.61 0 0–58
Target group
Adults in general 13 0.43*** 0.33–0.53 24 0–60 0.350
Women 4 0.54** 0.18–0.90 37 0–78
Older adults 4 0.29** 0.09–0.48 4 0–69
CBT v. other
CBT 13 0.40*** 0.28–0.53 35 0–65 0.585
Other 8 0.45*** 0.33–0.57 0 0–56
CBT, cognitive–behavioural therapy; MDD, major depressive disorder.
a. The data presented here are from analysis using the random effects model.
b. Variance between studies as a proportion of the total variance; heterogeneity tested using the I 2 statistic.
*P50.05, **P50.01, ***P50.001.




Comparisona comparisons g 95% CI I 2 95% CI P
All studies 14 0.27** 0.07–0.46 70 41–81
Outlier removedc 13 0.16** 0.05–0.27 4 0–49
Adjusted values 15 0.13 0.01–0.25
Effect size for depression 14 0.52*** 0.38–0.66 38 0–66
Adjusted values 17 0.44 0.28–0.59
One effect size per study
Highest 12 0.16 0.04–0.28 18 0–58
Lowest 12 0.16 0.04–0.27 16 0–57
Subgroup analyses
MDD
Yes 4 0.11 70.11–0.32 13 0–72 0.528
No 9 0.19** 0.05–0.32 18 0–62
Comorbidity
Yes 6 0.18* 0.02–0.33 13 0–66 0.843
No 7 0.15 70.02–0.33 22 0–67
Treatment type
Individual 10 0.17* 0.03–0.31 32 0–66 0.934
Group 3 0.18 70.07–0.43 0 0–90
Target group
Adults in general 7 0.16* 0.04–0.28 0 0–58 0.952
Women 3 0.07 70.49–0.62 65 0–88
Older adults 3 0.16 70.05–0.36 0 0–72
CBT v. other
CBT 10 0.18** 0.07–0.30 1 0–53 0.700
Other 3 0.12 70.18–0.41 46 0–84
CBT, cognitive–behavioural therapy; MDD, major depressive disorder.
a. The data presented here are from analysis using the random effects model.
b. Variance between studies as a proportion of the total variance; heterogeneity tested using the I 2 statistic.
c. Outlier’s effect size g= 2.16 (Scheidt et al).30
*P50.05, **P50.01, ***P50.001.
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effect size of g = 0.16 (95% CI 0.04–0.27). Finally we conducted
a number of subgroup analyses, but none of the included
moderators was significantly associated with the effect size of
the physical health component of QoL. The mean effect size of
depression severity was g= 0.52 (95% CI 0.38–0.66). Heterogeneity
was moderate (I 2 = 38, 95% CI 0–66). After adjustment for
publication bias the mean effect size decreased to g= 0.44 (95%
CI 0.28–0.59), with three missing studies.
Univariate meta-regressions showed no significant association
between the effect size of physical health component and the effect
size of depressive symptoms (slope 0.35, 95% CI 70.12 to 0.82,
P= 0.129) or the number of treatment sessions (slope 0.00, 95%
CI 70.03 to 0.03, P= 0.968). Similarly, the multivariate meta-
regression demonstrated that none of the predictors was
significantly related to the effect of psychotherapy for depression
on the physical health component of QoL at post-treatment
assessment (Table 4).
Discussion
We examined the effects of psychotherapy on QoL of people with
depression, separately for global QoL and for its mental and
physical health components. The results were in line with previous
findings, suggesting that psychotherapy for depression is beneficial
not only for depressive symptoms but also for quality of life.9,13
Psychotherapy resulted in larger improvements in QoL than
control conditions. The largest effect size was identified for the
mental health component, whereas the effect size for global QoL
was moderate. The smallest effect size was detected for the
physical health component, which, however, included a limited
number of comparisons. Nevertheless, even after excluding an
outlier and adjusting for publication bias, the effect size for the
physical health component remained statistically significant.
Overall, it can be concluded that psychotherapy has a positive
impact on various domains of a patient’s life, such as mental
functioning, social and work-related relationships, level of
discomfort and engagement in everyday activities. Our findings,
in conjunction with previous work, demonstrate the efficacy of
psychotherapy for outcomes associated with depression.31
Particularly, the magnitude of the improvement in QoL is
















Fig. 3 Relationship between effect sizes for depressive
symptom severity and the mental health component of quality
of life.
Table 4 Study characteristics predicting the effect size of quality of life: multivariate meta-regression
B 95% CI s.e. P
Global component
Depression effect size 0.37 70.11 to 0.85 0.23 0.122
Number of sessions 70.01 70.05 to 0.02 0.02 0.380
Target group: adults v. elderly 0.00 70.48 to 0.48 0.23 0.999
Control group: care as usual v. waiting list 70.05 70.34 to 0.24 0.14 0.732
Control group: other v. waiting list 0.03 70.26 to 0.28 0.13 0.824
CBT v. other 0.00 70.24 to 0.22 0.11 0.994
Life review v. other 70.23 70.71 to 0.25 0.23 0.326
MDD 0.12 70.08 to 0.32 0.11 0.272
Comorbidity 70.22 70.53 to 0.08 0.15 0.143
Internet-based treatment 70.11 70.38 to 0.15 0.13 0.370
Constant 0.34 70.17 to 0.85 0.24 0.177
Mental health component
Depression effect size 0.50 0.16 to 0.83 0.15 0.007
Number of sessions 70.01 70.04 to 0.02 0.01 0.466
Target group: adults v. elderly 0.07 70.24 to 0.38 0.14 0.621
Target group: women v. elderly 0.22 70.27 to 0.70 0.22 0.345
CBT v. other 0.03 70.23 to 0.20 0.09 0.783
MDD 0.18 70.17 to 0.22 0.18 0.319
Comorbidity 70.06 70.30 to 0.17 0.11 0.580
Constant 0.21 70.15 to 0.57 0.17 0.223
Physical health component
Depression effect size 0.34 71.05 to 1.73 0.50 0.535
Number of sessions 0.01 70.30 to 0.25 0.09 0.902
Target group: adults v. elderly 70.18 72.12 to 1.17 0.70 0.815
Target group: women v. elderly 70.29 71.66 to 1.07 0.49 0.587
CBT v. other 70.06 71.25 to 1.14 0.43 0.903
MDD 70.05 71.08 to 0.99 0.37 0.902
Comorbidity 0.05 71.61 to 1.71 0.60 0.935
Individual treatment 70.04 70.91 to 0.84 0.32 0.912
Constant 0.07 73.54 to 3.68 1.30 0.980
CBT, cognitive–behavioural therapy; MDD, major depressive disorder.
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functioning of patients with depression.31 The influence of
psychotherapy on domains of patients’ lives other than the
depressive symptoms is important because it can reduce the
overall burden caused by the disease and decrease the risk of
future depressive episodes.12,32
We examined the association between QoL and depressive
symptom severity by conducting various meta-regression analyses.
The results were different for the global QoL and each of the two
specific components of QoL. We found a significant positive
relationship between the effect sizes for the mental health
component and the effect sizes for depressive symptoms in the
multivariate model. Nevertheless, the effect sizes for the physical
health component were not related to the effect sizes for
depressive symptoms. Finally, the relationship between the effect
sizes for global QoL and depressive symptom severity were not
statistically significant in the multivariate model. Overall, changes
in QoL were not fully explained by changes in depressive
symptoms. We can thus infer that decreased depressive symptom
severity at the end of the treatment is not necessarily a
manifestation of improvement in QoL of the patient or vice versa.
This is an indication that QoL and depressive symptoms are two
different constructs and that it is informative to use both as
treatment outcomes. It should be highlighted that the applied
research design did not allow us to determine causal or temporal
relationships between QoL and depressive symptoms. A
longitudinal design with repeated measurements of QoL and
depressive symptoms is needed to examine whether changes in
depressive symptoms lead to changes in QoL or vice versa.33
The effect sizes for depressive symptom severity were larger
than the effect sizes for QoL. This finding is in line with previous
studies demonstrating that impairments in QoL persist even after
patients reach remission.14,15 As a result, distortion in daily life
may endure even when deficits related to depressive symptoms
have ceased.9 A possible explanation is that improvements in
QoL follow a slower pace than those in depressive symptoms.13
In addition, participants were eligible for the clinical trials because
they experienced depressive symptoms and not because they
reported low QoL. Therefore, they may not all have had low
QoL to start with and thus had less to gain in terms of
improvement in QoL. Finally, the detected difference in the effect
sizes may also reflect the target of psychotherapy on reducing
depressive symptom severity.
We found that the effects of psychotherapy on global QoL
were larger for studies including exclusively participants with a
diagnosis of major depressive disorder at baseline. Previous
research has shown that deterioration of QoL is proportional to
the severity of depression.34,35 Psychotherapy is therefore an
effective treatment for people who experience both severe
depressive symptoms and serious distress in their QoL. Further-
more, studies including adult patients yielded larger effect sizes
than those including older adults. Older patients with depression
demonstrate extensive age-related needs that may obstruct the
efficacy of psychotherapy.36 In addition, debilitated QoL in older
adults may be related to risk factors other than depression, which
are not the explicit target of psychotherapy.37
Limitations of the study
The concept of QoL is inherently subjective and consequently is
hard to measure with precision. It is thus possible that the
different measures of QoL assessed slightly different constructs
or parts of life. This limitation, however, applies mainly to the
meta-analysis of global QoL where various instruments were
included. The meta-analyses of the mental and physical health
components were measured predominantly with the Medical
Outcome Study Short Form. In addition, the number of studies
in the meta-analysis of the physical health component was limited.
Thus, we may have lacked adequate power to detect small effect
sizes. A larger number of studies would allow us to interpret the
results with more confidence, and therefore we strongly
recommend the administration of measures of QoL in future
clinical trials.14 Another limitation relates to the quality of the
included studies, which was not ideal. Researchers are encouraged
to follow precisely the recommended guidelines for conducting
and reporting randomised trials.38 Moreover, a concern for every
meta-analysis is the prevalence of publication bias. The test of
publication bias that we performed examines only whether the
funnel plot is symmetrical or whether studies with small sizes
are missing. This procedure may have limited power to detect
moderate publication bias and accordingly our results may
overestimate the true effect size of psychotherapy on QoL.39
Furthermore, we examined only the short-term effects of
psychotherapy; there is evidence that psychotherapy has long-term
effects on depressive symptoms,40 and it is therefore important to
examine the possible long-term effects on QoL as well. Finally, we
examined the effects of psychotherapy on QoL in comparison with
control conditions. A meta-analysis focusing on the respective
comparison between psychotherapy and pharmacotherapy for
depression would be of importance.
Implications
Overall, this meta-analysis demonstrates that psychotherapy for
depression is related to improvements in QoL. This evidence
amplifies the notion that psychotherapy is beneficial not only
for reducing depressive symptoms but also for improving
additional outcomes related to depression. These effects are
expected to reduce the enormous burden caused by depression
and improve the lives of people with the disorder. Finally, the
results indicate that QoL and depressive symptoms are two
different constructs, and thus QoL could be assessed as an
additional treatment outcome. Since the effects of psychotherapy
are different for each component of QoL, it is informative to
use specific scores for each domain, and not only an overall score
for global QoL.
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Search strings for PubMed (the search regards the update of the database as described 
in the manuscript): 
Search (("Affective Symptoms"[MESH] OR "depression"[MESH] OR "mood disorders"[MESH] AND 
"randomized controlled trial") AND Clinical Trial[ptyp] AND ( "2013/01/01"[PDat] : 
"2014/12/31"[PDat] ) AND Humans[Mesh] AND adult[MeSH])  
Filters: Publication date from 2013/01/01 to 2014/12/31; Humans; Adult: 19+ years 
 
Table DS1 Study characteristics 
First author, 
year 
















+ + + − SW 
Barlow, 
198642 
GRP Older adults 6 REM (22); WL 
(23) 
LSI CES-D − − + − USA 
Beeber, 
201043 
GSH Women 16 IPT (34); CAU 
(37) 
SF-12 CES-D − + + + USA 
Berger, 
201144 
GSH Adults with 
MDD 
10 CBT (25); 
WL(26) 
WHOQOL BDI-II + + + + SL+GE 




+ + − + UK 
Carlbring, 
201346 
GSH Adults with 
MDD 




+ + + + SW 
Chiesa, 
201247 
GRP Adults with 
MDD 
8 MBCT (9); PE 
(7) 
PGWBI HRSD + + + − IT 
Cramer, 
201148 
GRP Women 12 CBT (48); 
CAU (19) 
SF-12 PHQ-9 + + + + UK 
Dekker, 
201249 
GSH Adults with 
MDD and 
heart failure 
2 CBT (20); 
CAU (21) 
MLHFQ BDI-II + + + + US 
Dindo, 201250 GRP Adults with 
MDD and 
migraine 




+ − − − US 
Dobkin, 
201151 
IND Adults with 
Parkinson’s 
disease 
10 CBT (41); 
CAU (39) 





Adults 12; 6 CWD (80); 
PST (128); 
CAU (139) 
SF-36 BDI + + + + UK 
Duarte, 
200953 
GRP Adults with 
MDD and 
haemodialysis  
12 CT (41); CAU 
(40) 
KDQOL-SF BDI + + + + BR 
Fledderus, 
201254 
GSH Adults 9 ACT (125); 
WL (126) 
SF-36 CES-D + + + + NL 
Folke, 201255 GSH/GRP Adults with 
MDD and 
unemployed 
6 ACT (18); 
CAU (16) 
WHOQOL BDI + − + −  
Freedland, 
200956 




12 CBT (41); SUP 
(42); CAU 
(40) 
SF-36 HRSD; BDI + + + +  
Harley, 
200857 
GRP Adults with 
MDD 
16 DBT (10); WL 
(9) 
SOS HRSD; BDI − + + −  
Haringsma, 
200658 




− − + +  
Høifødt, 
201359 




+ + − −  
Hunter, 
201260 
GRP Adults with 
substance use 
disorders 
18 CBT (47); 
CAU (26) 
SF-12 BDI-II − − + +  
Johansson, 
201261 









+ + + +  
Johansson, 
201262 
GSH Adults with 
MDD 





+ + + +  
Kessler, 
200963 




BDI + + + +  
King, 200064 IND Adults with 
comorbid 
anxiety 
6 CBT (63); SUP 
(67); CAU 
(67) 
EQ-5D BDI + + + +  
Korte, 201265 GRP Older adults 8 LR (100); CAU 
(102) 
EQ-5D CES-D + + + +  
Laidlaw, 
200866 
IND Older adults 
with MDD 
8 CBT (20); 
CAU (20) 
WHOQOL BDI; GDS; 
HRSD 
+ + + −  
Lamers, 
201067 
IND Chronically ill 
older adults 
6 MPI (183); 
CAU (178) 
SF-36 BDI + + + +  




CES-D + + + − NL 










BDI-II + + + + SL 
Röhricht, 
201371 
 GRP Recurrent 
MDD 
20 BPT (11); WL 
(12) 
MANSA HRSD + + + + UK 
Savard, 
200672 
IND Women with 
breast cancer 
8 CT (21); WL 
(16) 
QLQ HRSD; BDI + + − + CA 
Scheidt, 
201330 
IND Women with 
fibromyalgia 
syndrome 
25 DYN (23); 
CAU (23) 
SF-36 HRSD + + + + GE 
Serfaty, 
200973 
IND Older adults 12 CBT (64); 
CAU (55) 
EQ-5D BDI-II + + + + UK 
Serrano, 
200474 
IND Older adults 4 LR (20); CAU 
(9) 
LSI CES-D − − + − SP 
Serrano, 
201275 
IND Older adults 
with MDD 
6 LR (23); PL (8) LSI; QLSD GDS + − + − SP 
Strong, 
200876 
IND Adults with 
MDD and 
cancer 
10 PST (91); CAU 
(92) 
EQ-5D SCL-20 + + + + UK 








+ − − − US 
Vernmark, 
201078 
GSH Adults with 
MDD 





+ + + + NL 
Warmerdam, 
200879 
GSH Adults 8; 5 CBT (46); PST 
(42); WL (63) 
EQ-5D CES-D + + + + NL 






SF-12 BDI; PHQ-9 + + + + UK 
Wong, 200881 GRP Adults with 
MDD 
10 CBT (163); 
WL (159) 
Q-LES C-BDI − + + + HK 
Wuthrich, 
201382 
GRP Older adults 
with anxiety 
12 CBT (27); WL 
(35) 
SF-12 GDS + + + + AU 
Zilcha-Mano, 
201483 
IND Adults with 
MDD 
20 SET (51); PL 
(50) 
SF-36 BDI + + + + US 
 
a.  GSH, Guided self-help via internet (except Fledderus et al);54 GRP, group treatment; IND, individual treatment. 
b. ACT, acceptance and commitment therapy; BAT, behavioural activation treatment; BPT, body psychotherapy; CAU, 
care as usual; CBT, cognitive–behavioural therapy; CT, cognitive therapy; CWD, Coping With Depression; DBT, dialectical 
behaviour therapy; DG, discussion groups; DYN, psychodynamic psychotherapy; EV, educational video; IPT, 
interpersonal psychotherapy; LR, life review; MBCT, mindfulness-based cognitive therapy; MPI, minimal psychological 
intervention; PE, psychoeducation; PL, placebo; PST, problem solving treatment; REM, reminiscence therapy; SET, 
supportive expressive therapy; SUP, supportive therapy; WL, waiting list. 
c. EQ-5D, EuroQol; KDQOL-SF, Kidney Disease and Quality of Life-Short Form; LSI, Life Satisfaction Index; MANSA, 
Manchester Short Assessment of Quality of Life; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PGWBI, 
Psychological General Well-being Index; QLQ, Quality of Life Questionnaire; Q-LES, Quality of Life Enjoyment and 
Satisfaction; QOLI, Quality of Life Inventory; SF, Short-Form Health Survey; WHO-5, Well-Being Index; WHOQOL, World 
Health Organization Quality of Life. 
d. BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; C-BDI, Beck Depression Inventory Chinese 
edition; CES-D, Center for Epidemiologic Studies Depression Scale; EPDS, Edinburgh Postnatal Depression Scale; GDS, 
Geriatric Depression Scale; HRSD, Hamilton Rating Scale for Depression; IDAS-D, Inventory of Anxiety and Depression 
Symptoms- General Depression Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; PHQ-9, Patient Health 
Questionnaire; SCL-20, Symptom Checklist – Depression Scale. 
e. Trial quality: intention to treat analysis, allocation concealment, blinding of outcome assessment, random sequence 
generation; + low risk of bias, − high risk of bias. 
f. AU, Australia; BR, Brazil; CA, Canada; GE, Germany; IT, Italy; HK, Hong Kong; NL, Netherlands; SL, Switzerland; SP, 
Spain; SW, Sweden; UK, United Kingdom; US, United States. 
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